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ABSTRACT
The susceptibility gene tor Cowden disease (CD), an autosomal domi­
nant inherited cancer syndrome, has recently been mapped to an approx­
imately 6-cM interval on chromosome subband 10q22-23 between the 
markers D10S541 and D10S564 . CD is characterized by hamartomas of 
many organ systems, including the thyroid, breast, skin, and gastrointes­
tinal tract, as well as carcinoma of the thyroid and breast. Follicular 
thyroid adenomas and carcinomas are significant component tumors in 
CD,* thus, we sought to examine their sporadic counterpart tumors for loss 
of heterozygosity (LOH) of microsatellite markers in the 20-cM region 
within and flanking the Cowden critical interval. In all, 38 sporadic 
thyroid tumors were analyzed. LOH within the CD interval was observed 
in 5 of 19 (26%) follicular thyroid adenomas and 1 of 9 (11%) Hiirthle cell 
adenomas. Furthermore, of these adenomas with LOH, 3 of 4 (75%) were 
atypical follicular adenomas, whereas 2 of 15 (13%) were typical follicular 
adenomas. Surprisingly, no LOH was detected in this region in 10 follic­
ular carcinomas. The shortest region of overlap includes the markers 
DIOS1735 and D10S1739 . If the LOH observed in these sporadic tumors 
is related to the CD gene, then the Cowden critical interval can be revised 
to lie within the interval defined by D20S579  and D10S564. LOH in this 
narrow interval implicates the CD gene, or another gene in that interval, 
in follicular thyroid tumorigenesis. However, this does not explain the lack 
of LOH in follicular carcinomas. Taken together, it may instead be 
evidence against a stepwise progression from atypical adenomas to carci­
nomas. Alternatively, sporadic thyroid adenoma formation may be inde­
pendent of that locus, but loss of this region could prevent carcinoma 
formation, thus implying that the CD  gene may be an oncogene or growth 
promoter.
INTRODUCTION
nant condition of thyroid carcinoma (2, 4, 5). Follicular adenomas and 
follicular carcinomas are the predominant histology in CD.
The putative CD gene has recently been mapped to 10q22-23 (6), 
Manifestations of CD involve derivatives of endoderm, mesoderm, 
and ectoderm; thus, the yet-to-be-identified susceptibility gene will 
likely prove to be an important regulator of both development and 
neoplasia. Despite the apparent rarity of CD, the syndrome and the 
susceptibility gene will be a good model system for the study of 
susceptibility to, as well as the etiology and pathogenesis of, neoplas­
tic development: (a) the susceptibility gene will likely prove to be an 
important regulator of development in all three germ layers; (b) the 
hallmark of CD is hamartomas; thus, the gene will likely lend clues to 
the study of giowth, overgrowth, and malignant transformation; (c) 
two CD component tumors (breast and thyroid) have common spo­
radic counterparts, and the CD susceptibility gene may well play a 
prominent role in the pathogenesis of these sporadic tumors.
Because follicular thyroid adenomas and carcinomas are major 
component tumors of CD, it is possible that the CD gene, although 
being mutated in the germ-line of CD patients, may also be involved 
in the development of sporadic follicular thyroid tumors as a result of 
somatic mutation. Gross LOH along 1 Oq has previously been reported 
in sporadic follicular thyroid adenomas and carcinomas (7). However, 
markers within the Cowden region have not been examined previ­
ously. Therefore, to determine whether the Cowden locus on 
10q22-23 plays a pathogenetic role in the formation of sporadic 
follicular adenomas and carcinomas of the thyroid, we analyzed a 
series of 38 tumors for LOH at microsatellite markers in the Cowden 
critical interval.
Follicular thyroid tumors are commonly sporadic but are also found 
in genetic conditions such as the rare inherited cancer syndrome CD.3 
CD, an autosomal dominant trait with variable expression, is charac­
terized by hamartomas involving multiple organ systems derived from 
all three germ cell layers and a high risk of breast and thyroid cancers 
(1,2). Estimates of up to 50% lifetime risk of breast cancer in affected 
females and up to 10% lifetime risk of thyroid cancer in affected 
individuals have been cited (1-3). Thyroid gland abnormalities are the 
most frequently reported noncutaneous lesions in CD, affecting ap­
proximately two-thirds of these patients. These abnormalities include 
the benign conditions of goiter, adenoma, hyperthyroidism, hypothy­
roidism, thyroiditis, and thyroglossal duct cysts, as well as the malig­
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MATERIALS AND METHODS
Tumor Specimens« In all, 38 sporadic follicular thyroid tumor samples 
were obtained. Of these 38 samples, 10 were follicular carcinomas, 9 were 
Hiirthle (oxyphil cell) adenomas, and 19 were nonfunctioning follicular ade­
nomas. The histopathological classification was as suggested by the WHO 
committee (8),
DNA Preparation. Tumor tissue was collected at the time of surgery and 
snap-frozen. High molecular weight DNA was obtained from the tissue by 
phenol-chloroform extraction and ethanol precipitation (9). Sections from each 
of the tumors were histopathologically examined to ensure that the tumor to be 
analyzed was representative of the sample as a whole. All tumor samples 
contained greater than 60% tumor cells. The patients’ constitutional DNA was 
obtained either by DNA extraction from blood leukocytes or from normal 
thyroid tissue using standard procedures (9).
Detection of LOH. The interval containing the CD gene, DWS541 to 
D10S564, was originally determined to span 5 cM (10). However, recent 
mapping of this region suggests that this interval in fact spans a distance 
of 6 cM (11). Nine dinucleotide-repeat microsatellite markers located on lOq 
in the interval known to contain the CD gene and the flanking regions 
directly adjacent to it were used; DJ0S219 (AFM240wg7); D10S551 
(AFM240vfl0); D10S541 (AFM205xe3); D10S1765 (AFM337xf9); D10S579 
(AFM282ycl); DJ0S7 735 (AFM269xf9);Di0577J9(AFMb362yg5);Di0556^ 
(AFM029xhl2); and D10S583 (AFM289zh5; Ref. 11). D10S215 (6) was not
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used in this study because of erratic PCR amplification and the possible 
existence of a null allele.
PCR products were generated using a Touchdown thermal cycler (Hybaid 
Ltd.» Middlesex, United Kingdom) and the following protocol: 10 cycles of 
denaturation at 94°C for 1 min, annealing at 70°C for 1 min (decreasing 1°C 
each cycle until reaching 61°C), and extension at 72°C for 1 min; 25 cycles at 
94°C for 40 s, annealing at 55°C for 1 min, and extension at 72°C for 2 min; 
followed by 72°C for 10 min. The final concentrations of PCR reagents were 
as follows: 1 mM of each primer; 0.125 mM of each deoxyribonucleotide 
triphosphate; and IX PCR buffer containing 1.5 him MgCl2 (Perkin-Elmer 
Corp., Norwalk, CT) and 0.3 ¡j,\ Taq polymerase (5 units//¿I; Perkin-Elmer 
Corp.). PCR reactions were performed in a final volume of 22 ¡jA.
Each forward primer used for PCR was 5'-tagged with the fluorescent dye 
labels HEX or 6-FAM (Genosys Biotechnologies, Inc., The Woodlands, TX). 
PCR products were electrophoresed on 6% denaturing polyacrylamide gels 
using an Applied Biosystems model 373A automated DNA sequencer (Ap­
plied Biosystems and Perkin-Elmer Corp.) and the Genescan —2500 ROX 
internal size standard (Genescan; Applied Biosystems), The results were 
analyzed by automated fluorescence detection using Genescan 672 collection 
and analysis software (Genescan; Applied Biosystems). Scoring of LOH was 
performed by inspection of the Genescan analysis output. A double peak 
observed for the microsatellite marker amplified from DNA extracted from the 
blood sample indicated a heterozygote. A single peak in DNA extracted from 
the corresponding tumor sample indicated a loss of one allele. If normal cells 
were mixed with tumor cells, a minimum ratio of 1.5:1 of germ-line DNA peak 
to tumor DNA peak was also considered as LOH.
RESULTS
DNA from 38 thyroid tumors was screened for LOH using 9 
microsatellite markers between and including D10S219 and D10S583, 
a 20-cM interval. All tumors were informative for at least three 
markers between and including D10S541 and D10S564. LOH was not 
detected at any of these loci in 10 follicular carcinomas (Fig. 1). LOH 
between the markers D10S541 and D10S564, representing the 
Cowden critical interval, was identified in 1 of 9 (11%) Hiirthle cell 
adenomas and 5 of 19 (26%) follicular adenomas (Fig. 1). Interest­
ingly, 3 of 4 (75%) atypical follicular adenomas had LOH within the 
Cowden interval compared to 2 of 15 (13%) typical follicular adeno­
mas. Of note, sample 13 (the Hiirthle cell adenoma) was shown to 
have LOH only at DIOS1735 and D10S1739. Flanking markers 
D10S579 and D10S564 remained heterozygous. In sample 20, LOH 
was observed at D10S1765 and D10S579 and might extend to include 
D10S1735 and D10S1739 as well. Unfortunately, the latter two mark­
ers were homozygous {i.e. noninformative) in this sample. Inspection 
of the overall pattern of LOH in the Cowden critical interval demon­
strated that the SRO included the markers DIOS1735 and DIOS 1739
(Fig. 1).
Whereas one deletion unit was observed within the Cowden critical 
interval, it seemed that there were two additional deletion units: (a) 
one unit involving at least the marker D10S551 and the regions 
centromeric to it (e.g., samples 13 and 16); and (b) the second unit 
involving the marker D10S5S3 (e.g., samples 27 and 30; Fig. 1). LOH 
in these regions is consistent with those reported previously by 
Zedenius et cil (7).
DISCUSSION
We found LOH in the region of the putative Cowden locus in over 
one-fourth of sporadic thyroid follicular adenomas but in none of the 
sporadic follicular carcinomas. This paradoxical observation is puz­
zling yet tantalizing. When considering the lack of LOH in the 
carcinomas, in the context of significant LOH in the adenomas, two 
opposing hypotheses can be made. The first, and perhaps more simple, 
of these hypotheses is that if the Cowden gene is involved in the 
pathogenesis of these sporadic follicular adenomas, LOH in this 
region is indirect evidence that it is functioning as a tumor suppressor 
gene, which, when inactive or dysfunctional, could result in cellular 
proliferation. The high frequency of LOH in atypical as compared to 
typical adenomas in this study seems to lend credence to this postu­
late, if one assumes that atypical adenomas frequendy progress to 
carcinomas, With the currently available data, it is unclear whether 
thyroid follicular carcinoma genesis progresses from adenoma to 
atypical adenoma to carcinoma or whether each of these entities is 
unrelated. The significant 10q22-23 LOH observed in these thyroid 
adenomas may suggest a combination of hypotheses: that progression 
of adenoma to atypical adenoma may be related to LOH in this region 
but that stepwise progression from atypical adenomas to carcinomas 
does not occur, i.e. atypical adenomas might be a genetically distinct 
entity from follicular carcinoma. However, studies of different genetic 
alterations present in both thyroid adenomas and carcinomas, specif­
ically activating point mutations of the ras proto-oncogene (12, 13) 
and either LOH or translocation at 3p (14), would argue that thyroid 
adenomas can in fact progress to thyroid carcinomas, An alternative 
explanation for the observation of the present study would be that only 
point mutations occur in the putative Cowden gene in those sporadic 
adenomas destined for progression to carcinomas. This explanation 
cannot be excluded at present.
A second hypothesis is that the Cowden locus is an oncogene or
Tum or samples
Fig. 1. LOH analysis of markers within 
10q22~24 in 38 thyroid tumors. 1-10, follicular 
carcinomas; 7Í-79, Hürthle cell adenomas; 20-38, 
follicular adenomas, O, retention of heterozygosity; 
hatched circles, homozygosity (not informative); 
• ,  LOH. SRO, the SRO of markers involved in 
LOH. Chromosome 10 marker position has been 
determined by the arbitrary assignment of position 
0 for the marker D10S219 and subsequent 1-unit 
increments to represent I cM as described in the 
genetic map published by Généthon (11). *, the CD 
gene has previously been mapped to this region (see 
text).
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encodes a growth promoter. If this alternative hypothesis were true, 
adenoma formation would be independent of the Cowden locus, but 
loss of the Cowden locus would prevent carcinoma formation, thus 
implicating this locus as an oncogene. This might explain the obser­
vations that no LOH in the Cowden region is seen in the sporadic 
follicular carcinomas, that LOH in this region is observed in a sig­
nificant proportion of sporadic follicular adenomas (this study), and 
that no LOH has been observed in one breast carcinoma from a 
Cowden patient who belongs to a lOq-linked family (15). The overall 
implication of this final hypothesis is that in CD, germ-line point 
mutations in the Cowden gene result in gain of function. Which of 
these two opposing hypotheses is true is currently unknown, and 
further elucidation awaits isolation of the susceptibility gene.
LOH studies performed on DNA from tumors of sporadic origin 
have successfully been undertaken to facilitate the mapping of a 
number of tumor suppressor genes, including the recently identified 
BRCA2 (16-18). The SRO obtained in this study encompasses 
D10S1735 and DIOS1739. If this represents involvement of the 
Cowden locus in diese sporadic tumors, then the Cowden critical 
interval is between D10S564 and D10S579, a distance under 5 cM. 
Known genes within this interval, encoding glutamate dehydrogenase 
and aorta-specific actin 2, are likely poor candidates due to the 
function of their gene products in tissue unaffected in CD (19, 20). 
Two IFN-responsive genes, IFI-56K and IFI-54K (21), are better 
candidates, although excellent alternatives such as the Kox30 zinc 
finger gene ZNF32 (22) and H o xll  (23) might be telomeric to this 
region.
This LOH study has also helped to order the markers in the Cowden 
critical interval. The two markers D10S541 and DIOS1765 have 
previously been assigned an equivalent genetic position and presum­
ably are located on a single yeast artificial chromosome (11). Simi­
larly» DIOS1735 and DIOS579 have not been ordered and share an 
equivalent genetic position (11). The results reported in this study are 
now able to clearly order these markers based on contiguous stretches 
of LOH interrupted by definite regions of retained heterozygosity 
(Fig. 1). D10S541 would seem to be centromeric of DIOS1765 based 
on tumors 20 and 36, which show, in all likelihood, contiguous 
regions of LOH telomeric to D10S541 because D10S541 remained 
heterozygous in both tumors. D10S579 would seem to be centromeric 
of DIOS1735 based on tumor 13, which had a contiguous region of 
LOH telomeric to but not including D10S579 because there is reten­
tion of heterozygosity at DIOS579. Thus, the order of markers would 
be as follows: centromere; D10S541; D10S1765; D10S579\ 
DIOS1735; D10S1739; D10S564\ and telomere (Fig. 1).
It is interesting to observe that a number of genetic abnormalities 
involving chromosome 10 have now been implicated in thyroid neo­
plasia. Activating missense mutations of the RET proto-oncogene, 
mapped to 10qll.2, have been implicated in the development of 
medullary thyroid carcinoma, both within the familial cancer syn­
drome multiple endocrine neoplasia type 2 and in sporadic medullary 
thyroid carcinoma. RET has also been implicated in the development 
of sporadic papillary thyroid carcinoma by rearrangements that fuse 
the tyrosine kinase domain of RET with unrelated sequence, leading to 
the activation of RET  in these neoplasms (14). The current study 
suggests that a second gene on the long arm of chromosome 10, most 
likely the CD susceptibility locus, is involved in the genesis of 
sporadic follicular tumors.
Other genes implicated in the genesis of thyroid tumors include the 
adenomatous polyposis coli gene (APC), albeit at a very low fre­
quency (24), and the p53 gene in anaplastic carcinomas (13). The 
presence of thyroid neoplasms in patients with adenomatous polyposis 
coli is not uncommon; however, in Li-Fraumeni syndrome (associated 
with p53 germ-line mutation), thyroid neoplasms do not occur. Mu­
tations of the tumor suppressor gene p53 are present in many different 
sporadic tumors (25). p53 has a role in many pathways including 
apoptosis, DNA replication, DNA repair, and development; thus, the 
mutation of p53 in sporadic thyroid tumors should not be considered 
unusual.
In summary, we have found a distinct and small deletion unit within 
the Cowden critical interval at 10q22-23 that is found in sporadic 
follicular tumors. The surprising observation of LOH in sporadic 
adenomas, especially atypical ones, but not in carcinomas generates 
interesting and opposing hypotheses. The gene(s) within the deletion 
interval, which might represent the putative CD gene, could encode 
either a growth-promoting or growth-suppressing factor involved in 
the pathogenesis of both CD and sporadic thyroid tumors. The deter­
mination of which hypothesis is correct awaits the isolation and 
characterization of the susceptibility gene for CD,
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